Artivion, Inc. (NYSE: AORT) is a Healthcare company (Medical - Devices) with a market capitalization of $891M. The Maz Rating grades it against the other companies in its sector.
Artivion, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $18.27, Artivion, Inc. trades at 1.8x sales and 2.0x book value, with an EV/EBITDA of 29.8. Over the last twelve months it generated about $483M of revenue and a net loss of $18M. It runs a gross margin of 61.8%, an operating margin of 1.9% and a net margin of -3.7%. It shows return on equity of -3.9%, return on invested capital of 1.0% and a free cash flow yield of -4.9%. On the balance sheet: a debt-to-equity ratio of 0.91 and a current ratio of 4.42. Over the past 52 weeks the share price ranged from $18.11 to $48.25, with a beta of 1.28.
Artivion, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Artivion, Inc. (AORT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones and MSCI, and fails AAOIFI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 31.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.21% / 30% · Interest income / Revenue 0.08% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 31.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.21% / 33% · Receivables / Mkt Cap (36m) 9.25% / 49% · Interest income / Revenue 0.08% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 31.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.21% / 33.33% · Receivables / Mkt Cap (24m) 9.25% / 33.33% · Interest income / Revenue 0.08% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 31.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 6.35% / 33.33% · Receivables / Avg Assets (4Q) 11.0% / 33.33% · Interest income / Revenue 0.08% / 5% | Pass |
| FTSE | Debt / Total Assets 34.9% / 33.33% · (Cash+ST Inv) / Total Assets 4.64% / 33.33% · (Cash+Recv) / Total Assets 14.9% / 33.33% · Interest income / Revenue 0.08% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Artivion, Inc. (AORT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones and MSCI, and fails AAOIFI and FTSE.
No. Artivion, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.08% of each dividend: Artivion, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.